Literature DB >> 24097810

Neurovascular decoupling is associated with severity of cerebral amyloid angiopathy.

Stefano Peca1, Cheryl R McCreary, Emily Donaldson, Gopukumar Kumarpillai, Nandavar Shobha, Karla Sanchez, Anna Charlton, Craig D Steinback, Andrew E Beaudin, Daniela Flück, Neelan Pillay, Gordon H Fick, Marc J Poulin, Richard Frayne, Bradley G Goodyear, Eric E Smith.   

Abstract

OBJECTIVES: We used functional MRI (fMRI), transcranial Doppler ultrasound, and visual evoked potentials (VEPs) to determine the nature of blood flow responses to functional brain activity and carbon dioxide (CO2) inhalation in patients with cerebral amyloid angiopathy (CAA), and their association with markers of CAA severity.
METHODS: In a cross-sectional prospective cohort study, fMRI, transcranial Doppler ultrasound CO2 reactivity, and VEP data were compared between 18 patients with probable CAA (by Boston criteria) and 18 healthy controls, matched by sex and age. Functional MRI consisted of a visual task (viewing an alternating checkerboard pattern) and a motor task (tapping the fingers of the dominant hand).
RESULTS: Patients with CAA had lower amplitude of the fMRI response in visual cortex compared with controls (p = 0.01), but not in motor cortex (p = 0.22). In patients with CAA, lower visual cortex fMRI amplitude correlated with higher white matter lesion volume (r = -0.66, p = 0.003) and more microbleeds (r = -0.78, p < 0.001). VEP P100 amplitudes, however, did not differ between CAA and controls (p = 0.45). There were trends toward reduced CO2 reactivity in the middle cerebral artery (p = 0.10) and posterior cerebral artery (p = 0.08).
CONCLUSIONS: Impaired blood flow responses in CAA are more evident using a task to activate the occipital lobe than the frontal lobe, consistent with the gradient of increasing vascular amyloid severity from frontal to occipital lobe seen in pathologic studies. Reduced fMRI responses in CAA are caused, at least partly, by impaired vascular reactivity, and are strongly correlated with other neuroimaging markers of CAA severity.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24097810      PMCID: PMC3812103          DOI: 10.1212/01.wnl.0000435291.49598.54

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  22 in total

1.  Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria.

Authors:  K A Knudsen; J Rosand; D Karluk; S M Greenberg
Journal:  Neurology       Date:  2001-02-27       Impact factor: 9.910

2.  Parametric estimate of intensity inhomogeneities applied to MRI.

Authors:  M Styner; C Brechbühler; G Székely; G Gerig
Journal:  IEEE Trans Med Imaging       Date:  2000-03       Impact factor: 10.048

3.  Intracranial area: a validated method for estimating intracranial volume.

Authors:  Karen J Ferguson; Joanna M Wardlaw; C Louise Edmond; Ian J Deary; Alasdair M J Maclullich
Journal:  J Neuroimaging       Date:  2005-01       Impact factor: 2.486

4.  Imaging of amyloid burden and distribution in cerebral amyloid angiopathy.

Authors:  Keith A Johnson; Matt Gregas; John A Becker; Catherine Kinnecom; David H Salat; Erin K Moran; Erin E Smith; Jonathan Rosand; Dorene M Rentz; William E Klunk; Chester A Mathis; Julie C Price; Steven T Dekosky; Alan J Fischman; Steven M Greenberg
Journal:  Ann Neurol       Date:  2007-09       Impact factor: 10.422

5.  Functional magnetic resonance imaging detection of vascular reactivity in cerebral amyloid angiopathy.

Authors:  Andrew Dumas; Gregory A Dierksen; M Edip Gurol; Amy Halpin; Sergi Martinez-Ramirez; Kristin Schwab; Jonathan Rosand; Anand Viswanathan; David H Salat; Jonathan R Polimeni; Steven M Greenberg
Journal:  Ann Neurol       Date:  2012-07       Impact factor: 10.422

6.  11C-PIB binding is increased in patients with cerebral amyloid angiopathy-related hemorrhage.

Authors:  J V Ly; G A Donnan; V L Villemagne; J A Zavala; H Ma; G O'Keefe; S J Gong; R M Gunawan; T Saunder; U Ackerman; H Tochon-Danguy; L Churilov; T G Phan; C C Rowe
Journal:  Neurology       Date:  2010-02-09       Impact factor: 9.910

7.  Control of end-tidal PCO2 reduces middle cerebral artery blood velocity variability: implications for physiological neuroimaging.

Authors:  Ashley D Harris; Kojiro Ide; Marc J Poulin; Richard Frayne
Journal:  Neuroimage       Date:  2005-10-12       Impact factor: 6.556

8.  Spatial distribution of white-matter hyperintensities in Alzheimer disease, cerebral amyloid angiopathy, and healthy aging.

Authors:  Christopher M Holland; Eric E Smith; Istvan Csapo; Mahmut Edip Gurol; Douglas A Brylka; Ronald J Killiany; Deborah Blacker; Marilyn S Albert; Charles R G Guttmann; Steven M Greenberg
Journal:  Stroke       Date:  2008-02-21       Impact factor: 7.914

9.  Cerebral amyloid angiopathy: incidence and complications in the aging brain. II. The distribution of amyloid vascular changes.

Authors:  H V Vinters; J J Gilbert
Journal:  Stroke       Date:  1983 Nov-Dec       Impact factor: 7.914

10.  Matched case-control studies: a review of reported statistical methodology.

Authors:  Daniel J Niven; Luc R Berthiaume; Gordon H Fick; Kevin B Laupland
Journal:  Clin Epidemiol       Date:  2012-04-27       Impact factor: 4.790

View more
  55 in total

1.  Identification of neurovascular changes associated with cerebral amyloid angiopathy from subject-specific hemodynamic response functions.

Authors:  Rebecca J Williams; Bradley G Goodyear; Stefano Peca; Cheryl R McCreary; Richard Frayne; Eric E Smith; G Bruce Pike
Journal:  J Cereb Blood Flow Metab       Date:  2017-02-01       Impact factor: 6.200

Review 2.  Emerging concepts in sporadic cerebral amyloid angiopathy.

Authors:  Andreas Charidimou; Gregoire Boulouis; M Edip Gurol; Cenk Ayata; Brian J Bacskai; Matthew P Frosch; Anand Viswanathan; Steven M Greenberg
Journal:  Brain       Date:  2017-07-01       Impact factor: 13.501

3.  Cerebrovascular function in presymptomatic and symptomatic individuals with hereditary cerebral amyloid angiopathy: a case-control study.

Authors:  Anna M van Opstal; Sanneke van Rooden; Thijs van Harten; Eidrees Ghariq; Gerda Labadie; Panagiotis Fotiadis; M Edip Gurol; Gisela M Terwindt; Marieke J H Wermer; Mark A van Buchem; Steven M Greenberg; Jeroen van der Grond
Journal:  Lancet Neurol       Date:  2016-12-16       Impact factor: 44.182

4.  Age-dependent neurovascular dysfunction and damage in a mouse model of cerebral amyloid angiopathy.

Authors:  Laibaik Park; Kenzo Koizumi; Sleiman El Jamal; Ping Zhou; Mary Lou Previti; William E Van Nostrand; George Carlson; Costantino Iadecola
Journal:  Stroke       Date:  2014-04-29       Impact factor: 7.914

Review 5.  Diagnosis of Cerebral Amyloid Angiopathy: Evolution of the Boston Criteria.

Authors:  Steven M Greenberg; Andreas Charidimou
Journal:  Stroke       Date:  2018-01-15       Impact factor: 7.914

Review 6.  William M. Feinberg Award for Excellence in Clinical Stroke: Big Pictures and Small Vessels.

Authors:  Steven M Greenberg
Journal:  Stroke       Date:  2017-07-11       Impact factor: 7.914

7.  Vasomotion as a Driving Force for Paravascular Clearance in the Awake Mouse Brain.

Authors:  Susanne J van Veluw; Steven S Hou; Maria Calvo-Rodriguez; Michal Arbel-Ornath; Austin C Snyder; Matthew P Frosch; Steven M Greenberg; Brian J Bacskai
Journal:  Neuron       Date:  2019-12-03       Impact factor: 17.173

Review 8.  [Cerebral amyloid angiopathy and dementia].

Authors:  P Berlit; K Keyvani; M Krämer; R Weber
Journal:  Nervenarzt       Date:  2015-10       Impact factor: 1.214

9.  Topography of Cortical Microbleeds in Alzheimer's Disease with and without Cerebral Amyloid Angiopathy: A Post-Mortem 7.0-Tesla MRI Study.

Authors:  J De Reuck; F Auger; N Durieux; V Deramecourt; C Cordonnier; F Pasquier; C A Maurage; D Leys; R Bordet
Journal:  Aging Dis       Date:  2015-11-17       Impact factor: 6.745

10.  Cortical atrophy in patients with cerebral amyloid angiopathy: a case-control study.

Authors:  Panagiotis Fotiadis; Sanneke van Rooden; Jeroen van der Grond; Aaron Schultz; Sergi Martinez-Ramirez; Eitan Auriel; Yael Reijmer; Anna M van Opstal; Alison Ayres; Kristin M Schwab; Trey Hedden; Jonathan Rosand; Anand Viswanathan; Marieke Wermer; Gisela Terwindt; Reisa A Sperling; Jonathan R Polimeni; Keith A Johnson; Mark A van Buchem; Steven M Greenberg; M Edip Gurol
Journal:  Lancet Neurol       Date:  2016-05-11       Impact factor: 44.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.